Highest-materiality recent filing
Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026
Jeffrey Millard resigned as Chief Operating Officer on July 10, 2026.
Nasdaq notifies Ensysce of delisting risk for equity shortfall
Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.
Ensysce Q1 net loss $3.6M; cash $0.7M; Phase 3 trial 50% enrolled; strategic review underway
Net loss attributable to common stockholders $3.6M vs $1.9M in Q1 2025; R&D expense rose to $3.3M on Phase 3 costs.
Ensysce closes $2M preferred stock financing from prior $20M commitment; conversion price $0.55
Gross proceeds of $2M from second tranche under November 2025 agreement; net ~$1.9M for TAAP and MPAR programs and working capital.
Director Lee Rauch resigns from Ensysce board over severance package dispute
Lee Rauch resigned effective March 24, 2026, citing disagreement with board-approved severance packages.
Ensysce Biosciences receives Nasdaq deficiency notice for bid price below $1
Received Nasdaq deficiency letter on Feb 25, 2026; bid price closed below $1 for 30 consecutive business days.
Ensysce Biosciences closes $4M convertible preferred stock financing with up to $20M available
Closed $4M convertible preferred stock financing; up to $16M additional available in future tranches over 24 months.
Ensysce Q3 net loss $3.7M; Phase 3 PF614 trial started; FDA backs PF614-MPAR
Net loss attributable to common stockholders was $3.7M for Q3 2025, vs. a gain of $0.7M in Q3 2024.
Ensysce Biosciences reports Q2 2025 net loss of $1.7M, advances Phase 3 trial for PF614
Cash and equivalents $2.2M at June 30, 2025, down from $3.5M at Dec 31, 2024.
Net loss of $1.9M vs $3.1M in Q1 2024; R&D spend rose to $1.9M on PF614-MPAR activity.
Ensysce raises $2.2M via warrant exercise inducement; issues new warrants for 1.26M shares
Holders exercised 630,376 warrants at $3.24/share for cash; gross proceeds ~$2.2M before fees.
Ensysce Biosciences closes $1.1M registered direct offering and private placement of warrants
Gross proceeds of approximately $1.1M from sale of 315,188 shares (or equivalents) at $3.49/share.
Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner
Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.
Ensysce secures up to $10M R&D funding from Galephar in equity-based development deal
Galephar commits up to $10 million to support R&D, manufacturing, and testing of PF614 and PF614-MPAR.
Ensysce reports Q3 net income of $0.7M; awarded $14M NIH grant for PF614-MPAR
Net income of $0.7M vs net loss of $2.7M in Q3 2023; driven by $3.4M in federal grant revenue.
Ensysce Biosciences raises $5M in concurrent registered direct offering and warrant exercise
Gross proceeds of $5M from sale of 3.55M shares (or equivalents) at $0.47 per share and exercise of 7.2M outstanding warrants at reduced price.
Ensysce Biosciences receives Nasdaq delisting notice for equity shortfall
Notice received August 20, 2024; non-compliance with $2.5 million stockholders' equity minimum as of June 30, 2024.
Ensysce regains Nasdaq compliance with equity requirement, common stock continues trading
Received notice on May 24, 2024 from Nasdaq of regained compliance with Listing Rule 5550(b)(1) equity requirement.
Ensysce Biosciences reports Q1 net loss of $3.1M; advances PF614 Phase 3 plans
Net loss attributable to common stockholders was $3.1M for Q1 2024, vs $2.2M in Q1 2023.
Company believes it now has at least $2.5M stockholders' equity, satisfying Nasdaq listing rule.
Received Nasdaq deficiency letter on March 27, 2024 for bid price closing below $1.00 for 30 consecutive business days.
Ensysce reports FY2023 net loss of $10.6M; cash $1.1M; FDA Breakthrough for PF614-MPAR
Net loss Q4 2023 $3.5M vs $5.5M; full year $10.6M vs $25.1M (prior year).
Ensysce raises $4.7M via warrant exercise, issues new warrants at $1.06
Gross proceeds ~$4.7M from cash exercise of 3,601,752 existing warrants at reduced price $1.31 per share.
Notified on Nov 13, 2023 of non-compliance with Nasdaq Rule 5550(b)(1) due to stockholders' equity below $2.5M as of Sept 30, 2023.
Ensysce Q3 net loss narrows to $2.7M; cash $1.5M; PF614 study results expected by year-end
Net loss attributable to common stockholders was $2.7M ($0.87/share) vs $9.9M ($61.58) in Q3 2022.
Ensysce Biosciences raises $1.7M in convertible note and warrant private placement
Aggregate investment of $1.7M through senior secured convertible notes and warrants; initial close of $566,667 on or before Oct 26.
Ensysce Biosciences Q2 net loss $2.2M; cash $3.8M; IRB approves key PF614 study
Net loss for Q2 2023 was $2.2 million versus $7.9 million in Q2 2022; EPS ($0.98) vs ($56.49).
Ensysce Biosciences regains compliance with Nasdaq equity requirement on June 13
Received formal notice from Nasdaq that it now meets the equity requirement under Listing Rule 5550(b)(1).
Ensysce completes $7M offering, believes it meets Nasdaq equity requirement
Raised ~$7M gross via public offering of common stock and warrants on May 12, 2023.
Ensysce closes $7M public offering of common stock and warrants
Offered 1,800,876 shares (or pre-funded warrants) plus Series A-1/A-2 warrants at $3.887 per unit.
Ensysce reports FY2022 net loss $24.2M, cash $3.1M; $3M equity raise; clinical milestones achieved
Q4 net loss $5.5M ($10.0M prior year); FY2022 net loss $24.2M ($29.1M prior year).
Ensysce Biosciences closes $3.0M registered direct offering of 3.57M shares at $0.84/share
Gross proceeds of $3.0M from sale of 3,571,431 common shares at $0.84 per share in registered direct offering.
Board declares dividend of 0.001 Series A Preferred share per common share; record date Feb 13, 2023.
The Company has appointed Dr. William K. Schmidt, Ph.D. as the Company's interim Chief Medical Officer, effective as of September 15, 2022.
tender of resignation from its Chief Medical Officer, Dr. Nily Osman, such resignation effective as of September 15, 2022.
On February 8, 2022, the Board of Ensysce Biosciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Lee Rauch to its Board of Directors (“Board”), effective immediately (the “New Director”).
Max materiality 0.85 · Median 0.60 · Most common event other_material